Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SVA.TO
- Price
- 0.17
- Stock movement up
- +- (%)
- Company name
- Sernova Corp
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 55.31M
- Ent value
- 70.29M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 40.85%
- 1 year return
- -63.83%
- 3 year return
- -52.03%
- 5 year return
- 5.51%
- 10 year return
- -1.61%
Last updated: 2025-04-15
DIVIDENDS
SVA.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 325.32M |
| EPS (TTM) | -0.13 |
| FCF per share (TTM) | -0.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -327.38K |
| Operating income (TTM) | -38.62M |
| Net income (TTM) | -38.93M |
| EPS (TTM) | -0.13 |
| EPS (1y forward) | -0.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.02M |
| Net receivables | 497.39K |
| Total current assets | 6.23M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 897.69K |
| Total assets | 7.46M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 19.51M |
| Total liabilities | 20.00M |
| Shareholder's equity | -12.55M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -26.32M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -26.32M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -522.11% |
| Return on Invested Capital | 310.21% |
| Cash Return on Invested Capital | 209.77% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.17 |
| Daily high | 0.18 |
| Daily low | 0.16 |
| Daily Volume | 76K |
| All-time high | 3.60 |
| 1y analyst estimate | 2.58 |
| Beta | 1.32 |
| EPS (TTM) | -0.13 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 Jun 2025 |
Downside potential
Loading...
Downside potential data
| SVA.TO | S&P500 | |
| Current price drop from All-time high | -95.28% | -12.04% |
| Highest price drop | -99.44% | -56.47% |
| Date of highest drop | 20 Mar 2009 | 9 Mar 2009 |
| Avg drop from high | -86.15% | -11.07% |
| Avg time to new high | 329 days | 12 days |
| Max time to new high | 6363 days | 1805 days |
COMPANY DETAILS
Marketcap
55.31M
Marketcap category
Small-cap
Description
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (T...
April 1, 2025
With the business potentially at an important milestone, we thought we'd take a closer look at Sernova Biotherapeutics...
March 23, 2025
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D
Dr. Calias to add Operational Depth and Cell Therapy Expertise to SernovaLONDON, Ontario and BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: P...
March 10, 2025
LONDON, Ontario and BOSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Ce...
March 5, 2025
LONDON, Ontario and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s C...
March 3, 2025
LONDON, Ontario and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cel...
February 3, 2025
LONDON, Ontario and BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cel...
January 30, 2025
LONDON, Ontario and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio...
January 13, 2025
LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio...
December 20, 2024
Signed Letter of Intent with ‘Project REEM Ventures’ for Product Development and Commercialization in the Kingdom of Saudi Arabia Renowned Diabetes Expert Dr. Robert Gabbay to Serve as Clinical Adviso...
December 2, 2024
Next page